IBB News and Press, iShares Biotechnology ETF From 06/16/22

AVDL's FT218 is going to get delayed further over a patent issue. However, there's a goalpost in sight now, and the date is June 2023. The company is cash-strapped. For further details see: Avadel: Further Delay, But Some Light At The End Of The Tunnel

In the last 12 months, I count four Ionis programs that failed. This series of failures does not generate confidence. So, despite some catalysts up ahead, I will stay away. For further details see: Ionis Pharma: Too Many Programs Have Failed To Produce Confidence

The private sector balance increased by over $112 billion in May 2022. Credit creation from commercial banks was strong at $116B+. The seasonal pattern is up from here until the end of September, however midterm election years tend to be flat until then. Fed rate increases and...

Two ongoing studies for use of paltusotine for treatment of patients with Acromegaly are PATHFNDR-1 and PATHFNDR-2; Results from both studies expected 2023. Paltusotine is also being explored for the treatment of patients with neuroendocrine tumors in a phase 2 study. Phase 1 proo...

A phase 2/3 trial failure in the MDD indication of PRAX-114 allows this biotech to shift focus over to PRAX-944 for Essential tremors and other preclinical drugs. Results from the phase 2b Essential1 study using PRAX-944 for treatment of patients with essential tremors expected 2...

Positive results have been released thus far from a phase 1 study using INBRX-101 for the treatment of patients with Alpha-1 Antitrypsin Deficiency. It is expected that the Alpha-1 Antitrypsin Deficiency Augmentation therapy market could reach $1.95 billion by 2026. If FDA gives g...

The healthcare sector is known for outperforming during times of recession and/or high inflation. That being the case, the well-diversified investor should consider allocating some capital to VHT: the Vanguard Healthcare ETF. YTD, the VHT ETF has outperformed the S&P500 by ~4%...

BBIO lost hugely after the December phase 3 flop. So, although its business model is very interesting, it is not de-risked. It does have a lot of cash. For further details see: BridgeBio Pharma: Yet To Be Proven Business Model

Today, we revisit Outlook Therapeutics for the first time since March 2021. The company recently temporarily withdrew its marketing application for its main asset, clouding the outlook on this small-cap name even further. Should shareholders bail out or hold tight onto the stock? ...

iShares Nasdaq Biotechnology ETF (IBB) - $0.0305. 30-Day SEC Yield of 0.24% as of April. 29. Payable Jun 15; for shareholders of record Jun 10; ex-div Jun 09. For further details see: iShares Nasdaq Biotechnology ETF declares quarterly distribution of $0.0305